The ROSCO panel developed a tracking tool to help clinicians continuously follow the disease developments of their rosacea patients that comprises clinical as well as quality-of life-features. This may contribute to facilitating the best possible individualised care.
In the wake of the change to a phenotype-based approach to rosacea, the Rosacea Consensus (ROSCO) group saw the need to develop a comprehensive longitudinal monitoring tool . Taking care of patients suffering from this chronic disease involves long-term management with modifications in therapy whenever clinical features change. The new Rosacea Tracker is supposed to offer an option to document changes in rosacea disease features for physicians, as well as an option to record patient-reported clinical changes and influence on patients’ quality of life. Collecting this evidence could enable the physician to decide if and when altering the management is indicated.
The global 2019 ROSCO ...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« Comorbidities more common in chronic urticaria, psoriasis, and AD Next Article
Above-the-neck melanoma more prone to metastases »
Table of Contents: EADV 2019
Spotlight on Psoriasis
New Insights in Photoprotection
Rosacea – from new spectrum to new therapy
Best of the Posters
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.